The green light from the U.S. FDA means that Xyzal, produced by Belgian drug company UCB, will be ready to hit U.S. pharmacy shelves in time for the 2007 autumn allergy season. Xyzal has been on sale in Europe since 2001 and is currently approved in over 80 countries worldwide.